Home Newsfeeds JP Morgan Upgrades Visteon to Neutral, Announces $129 Price Target

JP Morgan Upgrades Visteon to Neutral, Announces $129 Price Target

JP Morgan analyst Ryan Brinkman upgrades Visteon (NASDAQ:VC) from Underweight to Neutral and announces $129 price target.

byBenzinga Newsdesk

October 24, 2022

1 minute read

JP Morgan analyst Ryan Brinkman upgrades Visteon (NASDAQ:VC) from Underweight to Neutral and announces $129 price target.

Visa To Rally 15%? Here Are 10 Other Analyst Forecasts For Monday

By Lisa Levin

April 17, 8:19 AM

Raymond James boosted the price target for DexCom, Inc. (NASDAQ: DXCM) from $127 to $138. Raymond James analyst Jayson Bedford upgraded the stock from Outperform to Strong Buy. DexCom shares rose 1.8% to $117.75 in pre-market trading.

AXP

Ironwood’s Constipation Drug Shows Efficacy In Pediatric Patients

By Vandana Singh

September 6, 9:26 AM

Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) announced topline data from a Phase 3 trial evaluating Linzess (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation.

ABBV

Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?

By Vandana Singh

December 22, 11:12 AM

Senti Biosciences Inc (NASDAQ: SNTI) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hemato

SNTI